Terence Flotte, MD

• Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells

• Precision of Exon Skipping with U7 Constructs

• ESGCT 2021: Virtually Pan-European

• In vivo gene editing works in humans: Results of a phase 1 clinical trial for TTR amyloidosis

• Immune Responses to Recombinant Adenoviruses As Gene Therapy Vectors and COVID-19 Vaccines: A Two-Edged Sword

• Base Editing to the Rescue

• It Is Time to Call Anti-Asian Bias What It Is: Racism

• Gene Therapy in Global Health: Meeting the Needs of Chinese Patients with Beta-Thalassemia

• Women Lead Gene Therapy Science in 2021

• Supporting Families Considering Participation in a Clinical Trial: Parent-Provider Perspectives

• Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice

• Large-scale molecular epidemiological analysis of AAV in a cancer patient population

• Common pathways to Dean of Medicine at U.S. medical schools

• CRISPR/Cas-Dependent and Nuclease-Free In Vivo Therapeutic Gene Editing

• CRISPR Keeps Things Fresh: Next-Generation Tools for Gene Editing

• In Reply to Ramotshwana et al

• Liver targeting with rAAV7: balancing tropism with immune profiles

• Gene and Cell Therapy for Inherited and Acquired Immune Deficiency

• Writing the Story of Gene Editing and CRISPR: An Interview with Kevin Davies, PhD

• Science Policy and Funding Implications of the 2020 U.S. Election

• Two-Plasmid Packaging System for Recombinant Adeno-Associated Virus

• Black Lives Matter to Gene Therapy

• SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS

• Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy

• Accelerated Graduation and the Deployment of New Physicians During the COVID-19 Pandemic

• Barrie J. Carter: The Science and the Scientist

• Volume and Infusion Rate Dynamics of Intraparenchymal Central Nervous System Infusion in a Large Animal Model

• Revisiting the "New" Inflammatory Toxicities of Adeno-Associated Virus Vectors

• A Message to Our Community in the Midst of the COVID-19 Pandemic

• Impact on Women's Health: Gene Therapy in Gynecologic Oncology

• Free Gene and Cell Therapy Services Offered by the National Heart, Lung, and Blood Institute of the National Institutes of Health

• Muscle-Directed Delivery of an AAV1 Vector Leads to Capsid-Specific T Cell Exhaustion in Nonhuman Primates and Humans

• 2020: Gene Therapy Enters Its Fourth Decade

• Gene Therapy Untangles the Problem of Chronic Traumatic Encephalopathy

• Ringing in the Changes

• In Reply to Signer and Curtin and to Goyal et al

• Prime Editing: A Novel Cas9-Reverse Transcriptase Fusion May Revolutionize Genome Editing

• A Safe and Reliable Technique for CNS Delivery of AAV Vectors in the Cisterna Magna

• Women's Representation Among Members and Leaders of National Medical Specialty Societies

• Epigenome Editing Strategies for Low Back Pain

• Getting Tough on Capsid Screening: Tough Decoys Enable Barcoding of Vectors Capable of both Entry and Expression

• Senior Gene Therapy Scientists Take a Stand Against Human Embryo Gene Editing

• Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here?

• AAV9 gene replacement therapy for respiratory insufficiency in very-long chain acyl-CoA dehydrogenase deficiency

• New Horizons for Immune Gene Therapy

• Bridging from Intramuscular to Limb Perfusion Delivery of rAAV: Optimization in a Non-human Primate Study

• The Year in Review: The Top Five Papers of 2018

• What the Gene Therapy Community Should Do About Sexual Harassment

• Top Five Gene Therapy Stories of 2019

• Assuring Integrity in the Residency Match Process